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Microwave-assisted synthesis of 3-aminobenzo[b]-
thiophene scaﬀolds for the preparation of kinase
inhibitors†
Mark C. Bagley,*a Jessica E. Dwyer,a Maria D. Beltran Molina,b Alexander W. Rand,a
Hayley L. Randa and Nicholas C. O. Tomkinsonb
Microwave irradiation of 2-halobenzonitriles and methyl thioglycolate in the presence of triethylamine in
DMSO at 130 °C provides rapid access to 3-aminobenzo[b]thiophenes in 58–96% yield. This transform-
ation has been applied in the synthesis of the thieno[2,3-b]pyridine core motif of LIMK1 inhibitors, the
benzo[4,5]thieno[3,2-e][1,4]diazepin-5(2H)-one scaﬀold of MK2 inhibitors and a benzo[4,5]thieno[3,2-d]-
pyrimidin-4-one inhibitor of the PIM kinases.
Introduction
Benzothiophenes are naturally-occurring heterocycles, found
in petroleum deposits in their simplest form but also discov-
ered recently as a motif in more complex glycosides isolated
from the roots of E. grijissii.1 Benzothiophenes are important
components of organic semiconductors due to their potential
for elongated and highly delocalised electronic structures.2,3
Substituted benzothiophenes have also found application in
drug discovery as highly-privileged structures and valuable
building blocks in medicinal chemistry, being incorporated
into tubulin polymerisation inhibitors,4,5 acetyl-CoA carboxy-
lase inhibitors,6 antidepressants,7 and as estrogen receptor
modulators.8,9 Benzothiophenes are present in a number of
clinical agents, including Raloxifene,10 a selective estrogen
receptor modulator, Zileuton,11 an inhibitor of 5-lipoxygenase
and leukotriene biosynthesis used for the treatment of
asthma, and the antifungal agent Sertaconazole, which inhi-
bits the synthesis of ergosterol.12
Scaﬀolds based upon 2- or 3-aminobenzo[b]thiophenes
have enormous potential for further derivatization and have
shown great promise in fragment-based drug discovery and in
hit identification or lead development, including approaches
towards antimitotic agents5,13 and in the development of
inhibitors of kinase targets, such as the LIMK protein family,14
PIM-kinases15 and MAPK-2 kinase (MK2) (Fig. 1).16,17 A
number of 3-aminothieno[2,3-b]pyridine-2-carboxamide hits,
such as 1, were identified from high throughput screening
(HTS) as inhibitors of LIMK1, leading to the development of
tricyclic derivatives such as 2a and the benzothieno[3,2-d]pyri-
Fig. 1 Aminobenzothiophene scaﬀolds in drug discovery.
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midine 2b as a LIMK1 inhibitor lead candidate, to disrupt
actin polymerisation and thus prevent the metastatic potential
of tumour cells where LIMK is over-expressed.14
Benzothienopyrimidinones have been investigated as PIM
kinase inhibitors.15 The PIM kinases (PIM1, PIM2 and PIM3)
have been implicated in tumourigenesis and simultaneous tar-
geting of all three isoforms has presented itself as a promising
approach in cancer therapy, with PIM triple knockout mice
found to be viable and fertile.18 The benzothiophene scaﬀold
was again identified from an initial HTS hit,15 leading to the
development of a range of potent and selective benzo[b]thio-
phene-derived inhibitors such as 3 with nM activity (Ki values
of 2, 3 and 0.5 nM against PIM1, PIM2 and PIM3, respectively)
with oral bioavailability in mouse models.
Examples of aminobenzothiophene derivatives are also
found amongst inhibitors of the mitogen activated protein
kinase (MAPK) family of enzymes. These enzymes are essential
for inflammatory cell signalling events and contain historically
popular drug targets for inflammatory diseases, including
rheumatoid arthritis and Crohn’s disease because of their
involvement in the production of pro-inflammatory cyto-
kines,19 as well as being implicated in accelerated cellular
ageing in Werner syndrome (WS) via p38.20–23 MAPK-activated
protein kinase (MK2) is a rate-limiting kinase downstream of
p38 in the MAPK pathway and has been the subject of many
studies in recent years,24 as MK2 knock-out mice possess
normal healthy phenotypes whereas p38 knock-out mice are
lethal.25 The aminobenzo[b]thiophene derivative PF-3644022
shows excellent kinase selectivity for MK2, in vivo potency on a
nanomolar scale and projected ADME characteristics that
suggested it was suitable for oral human dosing.17,26,27 However,
PF-3644022 was found to result in hepatotoxicity in dogs27 and
so the analogue PF029 was developed and exhibited an improved
toxicological profile with no loss of cellular potency. This was
rationalized through installation of a metabolic shunt onto the
reactive diazepinone ring and extension of the biaryl ring section
to increase the compound’s cationic character, thus reducing its
molecular aﬃnity for transporter proteins.
As part of our interest in the synthesis of MAPK inhibitors
for the study of cellular ageing in Werner syndrome,20,28–33 the
benzothiophene scaﬀold, and its selectivity and cellular activity
profile for MK2 exemplified by PF-3644022, made it an attractive
target for synthesis. We have shown that treating young WS cell
cultures with p38 MAPK inhibitors can bring about a complete
reversal of the ageing phenotype, giving increased replicative
life-span, growth rates comparable to normal young cells and a
reduction in levels of F-actin stress fibres.20,23 These findings
suggested that WS could be amenable to therapeutic interven-
tion, but with high toxicity and poor kinase selectivity exhibited
in vivo by many p38 inhibitors,34–36 an inhibitor scaﬀold that
targeted the downstream kinase MK2 would oﬀer a promising
alternative target.20,37
With such a range of biological properties, there is a conti-
nuing interest in the search for new methods to access substi-
tuted benzothiophenes.38 One approach, with the potential to
incorporate diversity into a target library, would be to employ
transition metal-mediated processes from the corresponding
3-halobenzo[b]thiophenes.39 However, methods for the syn-
thesis of 3-halobenzo[b]thiophenes are currently fairly limited.
In particular, routes can be problematic when using ring halo-
genation due to the low reactivity of the heteroaryl unit and its
functional group compatibility.40–43 The 5-endo-dig halocyclisa-
tion of ortho-alkynylaryl thiophenol derivatives oﬀers an
alternative approach,44–48 but this requires installation of an
alkyne by metal-catalyzed cross-coupling followed by cyclisa-
tion, mediated by a halogen-containing electrophile, so can
exhibit a number of inherent disadvantages.
Herein, we present an annulation-based method for the
rapid preparation of 3-halo and 3-amino-2-substituted benzo-
[b]thiophenes suitable for elaboration to a range of kinase
inhibitors.49 It employs microwave irradiation as a convenient
platform for fast reaction kinetics, and to improve reaction
eﬃciency, and avoids the need for metal-catalyzed processes to
establish the parent heterocycle. This method is shown to be
suitable to access the pharmacophore of a range of biologi-
cally-active scaﬀolds for application in medicinal chemistry
and drug discovery.
Results and discussion
The benzothiophene-containing chemotypes appearing in
recent drug discovery programmes (Fig. 1) feature, or could in
principle be derived from, electron-poor aminobenzothio-
phene intermediates or their 7-aza analogues (Scheme 1). For
Scheme 1 Benzothiophene precursors to kinase inhibitors.
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example, the PIM kinase inhibitor scaﬀold 4 has been
accessed from 5-bromobenzothiophene 5a, using the halogen
as a handle for library diversification in a late-stage Suzuki
coupling.15 Similarly, it could be hypothesized that inhibitors
of MK2 for study in WS cells, such as PF-3644022 (Fig. 1),
could be prepared from the same core motif 5, using 5-nitro-
benzothiophene 5b, rather than by the functionalization of
6-nitroquinoline as reported by Anderson et al.17 This
approach would enable the synthesis of a range of diverse
chemical tools from a single common template. The original
route to MK2 hit compound 6a, prior to the development of
PF-3644022,16 employed cinnamic acid 8a in reaction with
thionyl chloride in chlorobenzene at 120 °C to establish the
3-chlorobenzothiophene scaﬀold 7a (Scheme 1).50 Unfortu-
nately this route would be wholly inappropriate for the syn-
thesis of benzothiophene 7b for elaboration to the desired
intermediate 6b on route to PF-3644022, as altering the substi-
tuent-directing eﬀects to a nitro group results in poor yields
and inseparable mixtures of 7b and 7c in the benzothiophene
synthesis, as well as giving other side products, as reported by
Higa.51 Hence an alternative route had to be sought.
Our first approach towards scaﬀold 6b used an alternative
and established method to access 3-halobenzothiophenes by
halogenation of the corresponding benzothiophene.40 The
condensation of methyl thioglycolate with 2-chloro-5-nitrobenz-
aldehyde (9) under basic conditions gave methyl 5-nitrobenzo[b]-
thiophene-2-carboxylate (10) in high yield (Scheme 2). We have
shown in previous work how microwave dielectric heating can
be used to dramatically reduce reaction times in the synthesis
of inhibitor scaﬀolds.30,32,33,37,52 Given that elevated tempera-
ture has promoted this,53,54 and a closely-related process for
the synthesis of 2-acetylbenzothiophenes,55 we carried out this
transformation under microwave irradiation at 90 °C to give
the benzothiophene 10 in good yield, whilst shortening the
reaction time from 17 h to 15 min. Selective halogenation at
C-3 of 10 was facilitated in a convoluted sequence of reactions
via the carboxylic acid 11 to overcome poor heterocycle reactiv-
ity.40 Saponification, again conducted by microwave dielectric
heating, under basic conditions was complete in 3 min at
100 °C and gave the carboxylic acid 11 in excellent yield. Sub-
sequent heating with excess bromine and sodium acetate in
glacial acetic acid did give 3-bromobenzothiophene 13 in good
yield after esterification using methyl iodide on a number of
occasions. However, the bromination was found to be highly
variable and eﬀorts to develop an alternative process using
microwave heating were constantly frustrated56 and so a more
reliable and eﬃcient route was sought. The poor yield of this
bromination reaction is catalogued in a recent report.57
In an alternative approach, our success in the microwave-
assisted synthesis of 10 was adapted to incorporate an amino
group at C-3, amenable by diazotization chemistry to provide
eﬃcient access to 3-bromobenzothiophene 13. The cyclocon-
densation of methyl thioglycolate with 2-nitrobenzonitriles
under basic conditions has been established by Beck,58–60 and
adapted methods with halide displacement have also been
reported.61–64 By switching the base from NaOMe61 to Et3N
63
and heating either 5-bromo-2-fluorobenzonitrile (14a) or
2-fluoro-5-nitrobenzonitrile (14b) and methyl thioglycolate
gave the corresponding 3-aminobenzothiophene 5a,b in very
high yield (Scheme 3), e.g. for 5b either at 100 °C in DMSO for
2 h using conductive heating (95% yield) or under microwave
irradiation at 130 °C for 11 min (94% yield), after simply
pouring the reaction mixture into ice-water and collecting the
product by filtration. Subsequent deaminative bromination60
of aminobenzo[b]thiophene 5b using tert-butyl nitrite in aceto-
nitrile in the presence of copper(II) bromide gave the target
bromobenzothiophene 13 in excellent yield by this much more
direct route.
The scope of this method was further explored by investi-
gating a number of substrates (Scheme 4, Table 1), suitable for
Scheme 2 Reagents and conditions: (i) K2CO3, DMF, RT, 17 h; (ii)
K2CO3, DMF, microwaves, 90 °C, 15 min; (iii) NaOH, MeOH–H2O, reﬂux,
3 h; (iv) NaOH, MeOH–H2O, microwaves, 100 °C, 3 min; (v) Br2, AcOH,
NaOAc, 55 °C, 48 h; (vi) MeI, K2CO3, DMF, RT, 3 h.
Scheme 3 Reagents and conditions: (i) Et3N, DMSO, 100 °C, 2 h; H2O;
(ii) Et3N, DMSO, microwaves, 130 °C, 11 min; H2O; (iii) tert-BuONO,
CuBr2, MeCN, 0 °C; RT, 2 h; HCl (aq.).
Scheme 4 Synthesis of benzothiophenes 5a–h and 7-aza–16.
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elaboration to a range of benzothiophene-containing scaﬀolds
found in drug discovery (Fig. 1).
It was found that the process was most eﬃcient for highly
electron-poor precursors, such as 14a–d (entries 1–4), and was
generally most eﬀective with 2-fluorides, but could also accom-
modate bromides and iodides albeit with reduced eﬃciency
(Table 1, entries 8 and 9). In most cases a very simple work up
procedure was eﬀective, providing benzothiophenes 5a–h in
65–96% yield in reaction times varying between 11 and
35 min, depending upon substrate. The eﬃciency compared
well to other available methods (cf. Table 1, entry 7, with Beck
synthesis of 5g,58 52% yield after 20 h), and so this method
was adopted as the route of choice to access the benzothio-
phene scaﬀold. Furthermore, it was possible to apply the pro-
cedure to the synthesis of 7-azabenzothiophene 16 using
2-halonicotinonitriles 15a–c. Interestingly, the choice of
halogen as substrate did not cause much variation in the yield
of azabenzothiophene product 16 (entries 11–13), which rep-
resents the core heterocyclic motif of the 3-aminothieno[2,3-b]-
pyridine-2-carboxamide inhibitors14 of LIMK1.
Having developed this rapid microwave-assisted method to
prepare benzothiophenes, the 5-nitro analogue 13 was further
elaborated to the benzo[4,5]thieno[3,2-e][1,4]diazepin-5(2H)-
one MK2 inhibitor scaﬀold 6b. Buchwald–Hartwig coupling of
(R)-tert-butyl (1-aminopropan-2-yl)carbamate (17) and bromo-
benzothiophene 13 gave a good yield of the N-arylated product
18 under microwave irradiation at 150 °C after 75 min
(Scheme 5). Subsequent Boc-deprotection using TFA and lacta-
mization by treatment with NaOMe using a modified pro-
cedure of Boschelli65 under conductive heating gave the MK2
inhibitor scaﬀold 6b, bearing suitable functionality for further
elaboration, in essentially quantitative yield.
Finally, an application of our microwave-assisted method to
access a pre-functionalized benzothiophene 5i for direct trans-
formation to a benzo[4,5]thieno[3,2-d]pyrimidin-4-one scaﬀold
21 as a chemical tool for PIM kinase inhibition15,66 was investi-
gated. This inhibitor exhibits subnanomolar to single-digit
nanomolar Ki values against all three PIM kinases and has
been co-crystallised with PIM1, guiding subsequent SAR
studies. It was postulated that rather than introducing the
cyclopropylvinyl group by a late-stage Suzuki coupling, in
accordance with the original diversification study, this group
could be incorporated from the start in order to access 20
directly. To that end, 2-fluorobenzonitrile 14i was prepared by
the Pd-catalyzed Suzuki–Miyaura coupling of 5-bromo-2-fluoro-
benzonitrile (14a) and the corresponding boronate ester at
80 °C,15 and heated with methyl thioglycolate in the presence
Table 1 Scope of the microwave-assisted synthesis of 3-amino ben-
zothiophenes 5a–h (Y = NH2) and the 7-aza analogue 16
Entry Substrate R X Z
Time/
mina Product
Yieldb
(%)
1 14a 5-Br F CH 11 5a 96
2 14b 5-NO2 F CH 11 5b 94
3 14c 5-Cl F CH 11 5c 92
4 14d 4-CF3 F CH 18 5d (R = 6-CF3) 80
5 14e 4-NO2 F CH 35 5e (R = 6-NO2) 67
6c 14f 5-Ph F CH 15 5f 85
7 14g H F CH 15 5g 65
8 14g H Br CH 15 5g 23
9 14g H I CH 15 5g 47
10 14h 5-CF3 F CH 20 5h 88
11 15a H F N 15 16 66
12 15b H Cl N 15 16 69
13 15c H Br N 15 16 51
aHold time at the given temperature, as measured by the in-built IR
sensor, by modulation of the initial microwave power. b Isolated yield
of product 5 or 16 after reaction according to Scheme 4, cooling in a
stream of compressed air and pouring the reaction mixture into iced
water. c Product was isolated by aqueous work up, followed by
purification by column chromatography on silica gel.
Scheme 5 Reagents and conditions: (i) Pd(OAc)2 (5 mol%), Cs2CO3,
(±)-BINAP (13 mol%), PhMe, microwaves, 150 °C, 75 min; (ii) TFA, CH2Cl2,
RT, 4.5 h; (iii) NaOMe, MeOH, 50 °C, 2 h; reﬂux, 2 h; HCl (aq.).
Scheme 6 Reagents and conditions: (i) trans-2-cyclopropyl-
vinylboronic acid pinacol ester, Pd(Ph3)2Cl2 (10 mol%), 1 M Na2CO3,
DME/EtOH/H2O, 80 °C, 16 h; (ii) Et3N, DMSO, microwaves, 130 °C,
35 min; (iii) 2-chloroacetonitrile, HCl, dioxane, RT, 16 h; (iv) Me2NH,
EtOH, RT, 16 h; SCX column, MeOH/CH2Cl2; NH3, MeOH.
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of Et3N in DMSO at 130 °C for 35 min under microwave
irradiation to give the corresponding benzothiophene 5i in
reasonable yield after purification by column chromatography
(Scheme 6). The cyclopropylvinyl group was found to be com-
patible with the subsequent chemistry: reaction of 5i with
chloroacetonitrile in 4 N HCl in dioxane gave chloromethyl
derivative 19 which, on reaction with dimethylamine, under-
went further cyclization to give the thienopyrimidinone scaﬀold
20 after purification by immobilization on an acidic resin. Thus
the method delivered this known PIM kinase inhibitor by an
extremely rapid route, suitable for biological study.
Experimental
Materials and methods
Commercially available reagents were used without further
purification; solvents were dried by standard procedures. Light
petroleum refers to the fraction with bp 40–60 °C and ether
refers to diethyl ether. Unless otherwise stated, reactions were
performed under an atmosphere of air. Flash chromato-
graphy was carried out using Merck Kieselgel 60 H silica or
Matrex silica 60. Analytical thin layer chromatography was
carried out using aluminium-backed plates coated with Merck
Kieselgel 60 GF254 that were visualised under UV light (at 254
and/or 360 nm). Microwave irradiation experiments were per-
formed in a sealed Pyrex tube using a self-tunable CEM Discover,
CEM Explorer or Biotage Initiator 2.5 EXP EU focused monomo-
dal microwave synthesizer at the given temperature using the
instrument’s in-built IR temperature measuring device, by
varying the irradiation power (initial power given in parentheses).
Fully characterized compounds were chromatographically
homogeneous. Melting points were determined on a Kofler
hot stage apparatus or Stanford Research Systems Optimelt
and are uncorrected. Specific rotations were measured at the
indicated temperature (in °C) using a ADP440 polarimeter (Bel-
lingham + Stanley) at the sodium D line and are given in deg
cm−3 g−1 dm−1 with concentration c in 10−2 g cm−3. Infra-red
spectra were recorded in the range 4000–600 cm−1 on a Perkin-
Elmer 1600 series FTIR spectrometer using an ATR probe or a
Shimadzu IRAﬃnity-1 equipped with an ATR accessory and are
reported in cm−1. NMR spectra were recorded using a Varian
VNMRS instrument operating at 400 or 500 MHz or a Bruker
Avance III 400 MHz or Bruker Avance DRX 500 MHz for 1H
spectra and 100 or 126 MHz for 13C spectra; J values were
recorded in Hz and multiplicities were expressed by the usual
conventions. Low resolution mass spectra were determined
using a Waters Q-TOF Ultima using electrospray positive
ionization, A Waters LCT premier XE using atmospheric
pressure chemical ionization (APcI), an Agilent 6130 single
quadrupole with an APcI/electrospray dual source, a Fisons
Instrument VG Autospec using electron ionization at 70 eV
(low resolution) or a ThermoQuest Finnigan LCQ DUO electro-
spray, unless otherwise stated. TOFMS refers to time-of-flight
mass spectrometry, ES refers to electrospray ionization, CI refers
to chemical ionization (ammonia), FTMS refers to Fourier trans-
form mass spectrometry, NSI refers to nano-electrospray ioniza-
tion and EI refers to electron ionization. A number of high
resolution mass spectra were obtained courtesy of the EPSRC
Mass Spectrometry Service at University College of Wales,
Swansea, UK using the ionization methods specified.
Synthetic procedures
General procedure for synthesis of 3-aminobenzo[b]thio-
phenes 5 from benzonitriles 14. A mixture of the benzonitrile
14 (1.0 equiv.), methyl thioglycolate (1.05 equiv.) and triethyl-
amine (3.1 equiv.) in dry DMSO (2 M) was irradiated in a
Biotage Initiator 2.5 EXP EU or CEM Discover microwave
synthesizer at 130 °C for the time specified (hold time) by
modulating the initial microwave power. After cooling to room
temperature in a stream of compressed air, the reaction
mixture was poured into ice-water and the resulting solid col-
lected, washed with water and dried in vacuo to give the
desired product.
Methyl 3-amino-5-bromobenzo[b]thiophene-2-carboxylate
(5a). 5-Bromo-2-fluorobenzonitrile (14a) (0.50 g, 2.50 mmol),
methyl thioglycolate (0.22 mL, 2.60 mmol) and triethylamine
(1.10 mL, 7.75 mmol) were reacted according to the above
general procedure for 11 min to give the title compound
(700 mg, 96%) as a brown solid, mp 170–171 °C (Found [ES+]:
285.9535. C10H9
79BrNO2S [MH] requires 285.9532); IR (neat)
νmax/cm
−1 3477 (N–H), 3363 (N–H), 2954 (C–H), 1681 (CvO);
1H NMR (400 MHz, d6-DMSO) δH/ppm 8.44 (1H, d, J = 1.9 Hz,
4-CH), 7.82 (1H, d, J = 8.6 Hz, 7-CH), 7.64 (1H, dd, J = 8.6, 1.9
Hz, 6-CH), 7.17 (2H, bs, NH2), 3.79 (3H, s, Me);
13C NMR
(101 MHz, d6-DMSO) δC/ppm 164.6 (C), 148.6 (C), 137.7 (C),
133.2 (C), 131.0 (C), 125.7 (CH), 125.2 (CH), 117.1 (CH), 96.1
(C), 51.4 (Me); m/z (ES) 286 (M[79Br]H+, 100%).
Methyl 3-amino-5-nitrobenzo[b]thiophene-2-carboxylate
(5b). 2-Fluoro-5-nitrobenzonitrile (14b) (0.50 g, 3.0 mmol),
methyl thioglycolate (0.30 mL, 3.3 mmol) and triethylamine
(1.3 mL, 9.3 mmol) were reacted according to the above general
procedure for 11 min to give the title compound (0.71 g, 94%) as an
orange solid, mp 243.4–244.1 °C (acetone) (lit.,67 mp 244–246 °C)
(Found [FTMS]: 253.0280. C10H9N2O4S [MH] requires 253.0278); IR
(neat) νmax/cm
−1 3445 (N–H), 3342 (N–H), 1681 (CvO), 1572
(NO2), 1432 (C–C), 1328 (NO2), 1276 (C–O), 1093 (C–O);
1H NMR
(500 MHz, d6-DMSO) δH/ppm 9.24 (1H, d, J = 2 Hz, 4-CH), 8.29
(1H, dd, J = 9, 2 Hz, 6-CH), 8.12 (1H, d, J = 9 Hz, 7-CH), 7.47 (2H,
bs, NH2), 3.82 (3H, s, Me);
13C NMR (100 MHz, d6-DMSO) δC/ppm
164.2 (C), 149.6 (C), 144.9 (C), 144.5 (C), 131.4 (C), 124.3 (CH),
122.0 (CH), 119.4 (CH), 96.8 (C), 51.4 (Me); m/z (EI) 252 (M•+,
100%), 219 (72). 1H and 13C NMR spectroscopic analyses were in
good agreement with literature data.67
Methyl 3-amino-5-chlorobenzo[b]thiophene-2-carboxylate
(5c). 5-Chloro-2-fluorobenzonitrile (14c) (0.50 g, 3.2 mmol),
methyl thioglycolate (0.30 mL, 3.36 mmol) and triethylamine
(1.38 mL, 9.92 mmol) were reacted according to the above
general procedure for 11 min to give the title compound
(710 mg, 92%) as a colourless solid, mp 170–172 °C (Found
[ES+]: 242.0039. C10H9
35ClNO2S [MH] requires 242.0037); IR
(neat) νmax/cm
−1 3477 (N–H), 3365 (N–H), 1681 (CvO), 1278
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(C–O); 1H NMR (500 MHz, d6-DMSO) δH/ppm 8.30 (1H, d, J =
2.1 Hz, 4-CH), 7.88 (1H, d, J = 8.6 Hz, 7-CH), 7.53 (1H, dd, J =
8.6, 2.1 Hz, 6-CH), 7.17 (2H, bs, NH2), 3.79 (3H, s, Me);
13C NMR
(126 MHz, d6-DMSO) δC/ppm 164.6 (C), 148.7 (C), 137.3 (C),
132.7 (C), 129.1 (C), 128.4 (CH), 125.0 (CH), 122.7 (CH), 96.2 (C),
51.4 (Me); m/z (ES) 242 (M[35Cl]H+, 100%). 1H NMR spectro-
scopic analyses were in good agreement with literature data.15
Methyl 3-amino-6-(trifluoromethyl)benzo[b]thiophene-2-car-
boxylate (5d). 2-Fluoro-4-(trifluoromethyl)benzonitrile (14d)
(0.50 g, 2.64 mmol), methyl thioglycolate (0.24 mL,
2.73 mmol) and triethylamine (1.14 mL, 8.20 mmol) were
reacted according to the above general procedure for 20 min
to give the title compound (580 mg, 80%) as a colourless
solid, mp 159–161 °C (Found [ES+]: 298.0120. C11H8F3NNaO2S
[MNa] requires 298.0124); IR (neat) νmax/cm
−1 3471 (N–H),
3344 (N–H), 2964 (C–H), 1664 (CvO); 1H NMR (400 MHz,
d6-DMSO) δH/ppm 8.38–8.32 (2H, 5-CH and 7-CH), 7.72 (1H, d,
J = 8.7 Hz, 4-CH), 7.26 (2H, bs, NH2), 3.82 (3H, s, Me);
13C NMR
(126 MHz, d6-DMSO) δC/ppm 164.5 (C), 148.8 (C), 138.9 (C),
134.1 (C), 128.4 (q, 2JC–F = 31.8 Hz, C), 124.2 (q,
1JC–F = 272.7 Hz,
C), 124.1 (CH), 121.0–120.7 (m, CH), 120.3–120.0 (m, CH), 97.4
(C), 51.5 (Me); m/z (ES) 276 (MH+, 100%).
Methyl 3-amino-6-nitrobenzo[b]thiophene-2-carboxylate (5e).
2-Fluoro-4-nitrobenzonitrile (14e) (0.50 g, 3.00 mmol), methyl
thioglycolate (0.28 mL, 3.15 mmol) and triethylamine
(1.29 mL, 9.30 mmol) were reacted according to the above
general procedure for 35 min to give the title compound
(510 mg, 67%) as a colourless solid, mp 228–231 °C (lit.,58 mp
229–231 °C) (Found [ES+]: 275.0101. C10H8N2NaO4S [MNa]
requires 275.0097); IR (neat) νmax/cm
−1 3489 (N–H), 3367 (N–
H), 1697 (CvO), 1624 (C–O); 1H NMR (400 MHz, d6-DMSO) δH/
ppm 8.90 (1H, d, J = 2.1 Hz, 7-CH), 8.37 (1H, d, J = 8.7 Hz,
4-CH), 8.19 (1H, dd, J = 8.7, 2.1 Hz, 5-CH), 7.30 (2H, bs, NH2),
3.83 (3H, s, Me); 13C NMR (101 MHz, d6-DMSO) δC/ppm 164.3
(C), 148.4 (C), 147.0 (C), 138.8 (C), 135.6 (C), 124.2 (CH), 119.8
(CH), 118.5 (CH), 99.8 (C), 51.7 (Me); m/z (ES) 253 (MH+, 20%),
252 (M•+, 100). 1H NMR spectroscopic analyses were in good
agreement with literature data.63
Methyl 3-amino-5-phenylbenzo[b]thiophene-2-carboxylate
(5f). 4-Fluoro-[1,1′-biphenyl]-3-carbonitrile (14f ) (0.30 g,
1.52 mmol), methyl thioglycolate (0.14 mL, 1.59 mmol) and
triethylamine (0.65 mL, 4.74 mmol) were reacted according to
a modified general procedure for 15 min. After cooling in
a stream of compressed air, EtOAc (25 mL) was added and the
solution was washed sequentially with water (3 × 25 mL) and
brine (3 × 25 mL), dried over MgSO4 and evaporated in vacuo.
Purification by flash chromatography on silica gel, eluting
with light petroleum–EtOAc (4 : 1), gave the title compound
(380 mg, 85%) as a colourless solid, mp 96–97 °C (Found [ES+]:
284.0741. C16H14NO2S [MH] requires 284.0740); IR (neat) νmax/
cm−1 3439 (N–H), 3338 (N–H), 2949 (C–H), 1658 (CvO); 1H
NMR (400 MHz, d6-DMSO) δH/ppm 8.54 (1H, s, 4-CH), 7.91
(1H, d, J = 8.5 Hz, 7-CH), 7.84 (1H, d, J = 8.5 Hz, 6-CH), 7.78
(2H, d, J = 7.5 Hz, 2′,6′-PhH), 7.51 (2H, app t, J = 7.5 Hz, 3′,5′-
PhH), 7.39 (1H, t, J = 7.5 Hz, 4′-PhH), 7.26 (2H, bs, NH2), 3.80
(3H, s, Me); 13C NMR (101 MHz, d6-DMSO) δC/ppm 164.8 (C),
149.9 (C), 139.6 (C), 138.0 (C), 136.2 (C), 132.2 (C), 129.0 (CH),
127.5 (CH), 127.2 (CH), 126.7 (CH), 123.6 (CH), 121.0 (CH),
95.0 (C), 51.2 (Me); m/z (ES) 284 (MH+, 100%).
Methyl 3-aminobenzo[b]thiophene-2-carboxylate (5g).
2-Fluorobenzonitrile (14g) (0.16 mL, 1.5 mmol), methyl thio-
glycolate (0.135 mL, 1.5 mmol) and triethylamine (0.63 mL,
4.5 mmol) were reacted according to the above general pro-
cedure for 15 min to give the title compound (203 mg, 65%) as
a purple solid, mp 107.6–107.8 °C (MeOH–H2O) (lit.,
58 mp
110–111 °C) (Found [ES+]: 208.0434. C10H10NO2S [MH] requires
208.0432); IR (neat) νmax/cm
−1 3434 (N–H), 3337 (N–H), 1659
(CvO), 1520, 1289 (C–O); 1H NMR (500 MHz, d6-DMSO)
δH/ppm 8.13 (1H, d, J = 8.1 Hz, 4-CH), 7.82 (1H, d, J = 8.1 Hz,
7-CH), 7.50 (1H, m, 6-CH), 7.39 (1H, m, 5-CH), 7.15 (2H, bs,
NH2), 3.78 (3H, s, Me);
13C NMR (101 MHz, d6-DMSO) δC/ppm
164.8 (CvO), 149.8 (3-C), 138.8 (7α-C), 131.4 (3α-C), 128.5
(6-CH), 123.8 (5-CH), 123.1 (4-CH), 123.1 (7-CH), 94.4 (2-C),
51.2 (Me); m/z (ES) 207 (M•+, 93%), 176 (30), 175 (100),
147 (34), 146 (37). NMR spectroscopic analyses were in good
agreement with literature data.59,68
Methyl 3-amino-5-(trifluoromethyl)benzo[b]thiophene-2-car-
boxylate (5h). 2-Fluoro-5-(trifluoromethyl)benzonitrile (14h)
(0.50 g, 2.6 mmol), methyl thioglycolate (0.24 mL, 2.73 mmol)
and triethylamine (1.14 mL, 8.20 mmol) were reacted accord-
ing to the above general procedure for 20 min to give the
title compound (640 mg, 88%) as a colourless solid, mp
140–141 °C (Found [ES+]: 298.0121. C11H8F3NNaO2S [MNa]
requires 298.0120); IR (neat) νmax/cm
−1 3468 (N–H), 3335
(N–H), 1664 (CvO); 1H NMR (400 MHz, d6-DMSO) δH/ppm
8.67 (1H, bs, 4-CH), 8.09 (1H, d, J = 8.5 Hz, 7-CH), 7.79 (1H,
dd, J = 8.5, 1.5 Hz, 6-CH), 7.34 (2H, s, NH2), 3.82 (3H, s, Me);
13C NMR (101 MHz, d6-DMSO) δC/ppm 164.5 (C), 149.3 (C),
142.5 (C), 131.3 (C), 124.9 (q, 2JC–F = 32.7 Hz, C), 124.5 (q,
1JC–F
= 272.1 Hz, C), 124.4 (C–H), 124.1 (m, C–H), 120.7 (m, C–H),
96.2 (C), 51.4 (Me); m/z (ES) 276 (MH+, 100%).
Methyl (E)-3-amino-5-(2-cyclopropylvinyl)benzo[b]thiophene-
2-carboxylate (5i). (E)-5-(2-Cyclopropylvinyl)-2-fluorobenzoni-
trile (14i) (0.25 g, 1.33 mmol), methyl thioglycolate (0.12 mL,
1.39 mmol) and triethylamine (0.57 mL, 4.12 mmol) were
reacted according to a modified general procedure for
35 min. After cooling in a stream of compressed air, EtOAc
(25 mL) was added and the solution was washed sequentially
with water (3 × 25 mL) and brine (3 × 25 mL), dried over
MgSO4 and evaporated in vacuo. Purification by flash chrom-
atography on silica gel, eluting with light petroleum–EtOAc
(4 : 1), gave the title compound (210 mg, 58%) as a colourless
solid, mp 131–132 °C (Found [ES+]: 274.0899. C15H16NO2S [M]
requires 274.0896); IR (neat) νmax/cm
−1 3481 (N–H), 3365 (N–
H), 1672 (CvO); 1H NMR (400 MHz, d6-DMSO) δH/ppm 8.12
(1H, d, J = 1.6 Hz, 4-CH), 7.71 (1H, d, J = 8.5 Hz, 7-CH), 7.50
(1H, dd, J = 8.5, 1.6 Hz, 6-CH), 7.12 (2H, bs, NH2), 6.53 (1H, d,
J = 15.8 Hz, CH), 5.93 (1H, dd, J = 15.8, 9.1 Hz, CH), 3.78
(3H, s, Me), 1.69–1.55 (1H, m, CH), 0.86–0.80 (2H, m,
CHH), 0.56–0.49 (2H, m, CHH); 13C NMR (101 MHz, d6-
DMSO) δC/ppm 164.8 (C), 149.7 (C), 136.9 (C), 135.2 (C), 133.7
(CH), 131.9 (C), 126.4 (CH), 126.4 (CH), 123.1 (CH), 119.4 (CH),
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94.9 (C), 51.2 (Me), 14.4 (CH), 7.1 (CH2); m/z (ES) 274 (MH
+,
100%).
(3R)-3-Methyl-9-nitro-1,2,3,4-tetrahydro-5H-[1]benzothieno-
[3,2-e][1,4]diazepin-5-one (6b). A solution of (R)-methyl 3-
((2-((tert-butoxycarbonyl)amino)propyl)amino)-5-nitrobenzo[b]-
thiophene-2-carboxylate (18) (0.30 g, 0.73 mmol) in TFA (10%
v/v in CH2Cl2) (5.7 mL, 7.3 mmol) was stirred at room tempera-
ture for 4.5 h. When salt formation was confirmed by TLC ana-
lysis [Rf 0.3 in MeOH–CH2Cl2 (1 : 9)] the mixture was
evaporated in vacuo. The residue was dissolved in a mixture of
MeOH (5 mL) and NaOMe (25 wt% in MeOH; 1 mL, 4.4 mmol)
and warmed to 50 °C for 2 h before heating at reflux for 2 h.
The reaction mixture was then allowed to cool to room tem-
perature, cooled in an ice bath, neutralized by the addition of
hydrochloric acid (1 M) and stirred at 0 °C for 30 min. The
resulting solid was isolated by filtration under reduced
pressure, washed with water and dried in air to give the title
compound (0.18 g, 100%) as a red powder, mp 337.4–342.4 °C
(dec.) (Found [ES+]: 278.0590. C12H1sN3O3S [MH] requires
278.0594); [α]24D +110.6 (c 0.04, MeOH); IR (neat) νmax/cm
−1
3307 (N–H), 1598 (CvO), 1501 (NO2), 1438 (C–C), 1318 (NO2),
1102 (C–N), 736 (N–H); 1H NMR (500 MHz, d6-DMSO) δH/ppm
9.03 (1H, d, J = 2 Hz, 10-CH), 8.22 (1H, dd, J = 9, 2 Hz, 8-CH),
8.05 (1H, d, J = 9 Hz, 7-CH), 8.02 (1H, m, 1-NH), 7.95 (1H, d, J =
3 Hz, 4-NH), 3.60 (1H, m, 3-CH), 3.39 (2H, m, 2-CH2), 1.16 (3H,
d, J = 7 Hz, Me); 13C NMR (125 MHz, d6-DMSO) δC/ppm 164.2
(5-C), 145.3 (C), 144.2 (C), 141.8 (C), 132.9 (C), 123.8 (7-CH),
120.8 (8-CH), 118.6 (10-CH), 108.6 (C), 50.6 (2-CH2), 47.6 (3-CH),
18.6 (Me); m/z (ES) 277 (M•+, 87%), 262 (24), 234 (29), 206 (30).
Methyl 5-nitrobenzo[b]thiophene-2-carboxylate (10), pre-
pared under ambient conditions. Methyl thioglycolate
(0.48 mL, 5.4 mmol) and K2CO3 (0.89 g, 6.5 mmol) were added
sequentially to a solution of 2-chloro-5-nitrobenzaldehyde
(1.01 g, 5.4 mmol) in DMF (6.5 mL) and the mixture was
stirred at room temperature for 17 h. The reaction was then
quenched in ice-water and the resulting solid collected,
washed with water and dried in vacuo to give the title compound
(1.22 g, 95%) as an oﬀ-white solid, mp 213.3–217.6 °C (lit.,69
mp 213–215 °C) (Found [FTMS + p NSI]: 255.0435.
C10H11N2O4S [MNH4] requires 255.0434); IR (neat) νmax/cm
−1
3093 (C–H), 1701 (CvO), 1528 (NO2), 1439 (C–C), 1342 (NO2),
1302 (C–O); 1H NMR (500 MHz, CDCl3) δH/ppm 8.80 (1H, d, J =
2 Hz, 4-CH), 8.32 (1H, dd, J = 9, 2 Hz, 6-CH), 8.20 (1H, s,
3-CH), 8.01 (1H, d, J = 9 Hz, 7-CH), 4.00 (3H, s, Me); 13C NMR
(125 MHz, CDCl3) δC/ppm 162.2 (C), 147.4 (C), 145.9 (C), 138.3
(C), 137.2 (C), 130.7 (3-CH), 123.6 (7-CH), 121.2 (9-CH), 120.9
(7-CH), 52.9 (Me); m/z (EI) 237 (M•+, 100%), 206 (63), 160 (25).
1H NMR spectroscopic analyses were in good agreement with
literature data.53,70
Methyl 5-nitrobenzo[b]thiophene-2-carboxylate (10), using
microwave-assisted conditions. A mixture of 2-chloro-5-nitro-
benzaldehyde (0.75 g, 4.0 mmol), methyl thioglycolate (0.45 mL,
5 mmol) and K2CO3 (0.67 g, 4.8 mmol) in DMF (4.5 mL) was
irradiated at 90 °C for 15 min (hold time) in a pressure-rated
glass tube (35 mL) using a CEM Discover microwave synthesizer
by moderating the initial power (100 W). After cooling in a flow
of compressed air, the reaction mixture was poured into water
and the resulting solid filtered under reduced pressure, washed
with water and dried in air to give the title compound (0.84 g,
88%) as an oﬀ-white solid, mp 216.8–218.5 °C (lit.,69 mp
213–215 °C), with identical spectroscopic properties.
5-Nitrobenzo[b]thiophene-2-carboxylic acid (11), using con-
ductive heating. A solution of aqueous NaOH (1 M; 5 mL,
5 mmol) was added to a solution of methyl 5-nitrobenzo[b]-
thiophene-2-carboxylate (10) (0.40 g, 1.7 mmol) in MeOH
(5.5 mL) and the mixture was heated at reflux for 3 h. After
cooling to room temperature, the solution was acidified with
1 M HCl (aq.) and the resulting solid filtered under reduced
pressure and dried in air to give the title compound (0.36 g,
95%) as an oﬀ-white powder, mp 241.4–242.7 °C (lit.,71 mp
239–241 °C) (Found [TOFMS]: 224.0020. C9H6NO4S [MH]
requires 224.0018); IR (neat) νmax/cm
−1 2844 (br, O–H), 1670
(CvO), 1600 (C–C), 1511 (NO2), 1344 (NO2), 1313 (C–O);
1H
NMR (500 MHz, CD3OD) δH/ppm 8.87 (1H, d, J = 2 Hz, 4-CH),
8.30 (1H, dd, J = 9, 2 Hz, 6-CH), 8.24 (1H, s, 3-CH), 8.15 (1H, d,
J = 9 Hz, 7-CH); 13C NMR (125 MHz, CD3OD) δC/ppm 164.8 (C),
148.9 (5-C), 147.5 (C), 140.3 (C), 140.0 (C), 132.0 (3-CH), 125.1
(7-CH), 122.3 (4-CH), 121.9 (6-CH); m/z (EI) 223 (M•+, 100%),
195 (38), 149 (37). 1H NMR spectroscopic analyses were in
good agreement with literature data.53
5-Nitrobenzo[b]thiophene-2-carboxylic acid (11), using
microwave-assisted heating. A mixture of methyl 5-nitrobenzo-
[b]thiophene-2-carboxylate (10) (0.20 g, 0.84 mmol), aqueous
NaOH solution (1 M; 2.5 mL) and MeOH (3.5 mL) was irra-
diated at 100 °C for 3 min (hold time) in a pressure-rated glass
tube (10 mL) using a CEM Discover microwave synthesizer by
moderating the initial power (100 W). After cooling in a flow of
compressed air, the reaction mixture was diluted with water,
acidified with 1 M HCl and the resulting solid was filtered
under reduced pressure, washed with water and dried in air to
give the title compound (0.16 g, 94%) as an oﬀ-white powder,
mp 241.3–242.1 °C (lit.,71 mp 239–241 °C), with identical spec-
troscopic properties.
3-Bromo-5-nitrobenzo[b]thiophene-2-carboxylic acid (12).
According to a modified literature procedure,57 bromine
(1.4 mL, 27 mmol) was added portion-wise to a solution of
5-nitrobenzo[b]thiophene-2-carboxylic acid (11) (1.0 g,
4.5 mmol) and anhydrous sodium acetate (1.13 g, 13 mmol) in
glacial acetic acid (28 mL) under N2. A reflux condenser was
fitted and the solution heated at 55 °C for 27 h. After cooling
to room temperature, the solution was poured into ice-water
and the resulting solid isolated by vacuum filtration and dried
in air to give the title compound (1.02 g, 75%) as a yellow
powder, mp 309.5–316.8 °C (lit.,40 mp 307–309 °C) (Found
[TOF MS]: 301.9126. C9H5
79BrNO4S [MH] requires 301.9123);
IR (neat) νmax/cm
−1 2961 (br, O–H), 1701 (CvO), 1600 (C–C),
1511 (NO2), 1347 (NO2), 1270 (C–O), 620 (C–Br);
1H NMR
(500 MHz, CD3OD) δH/ppm 8.83 (1H, d, J = 2 Hz, 4-CH), 8.39
(1H, dd, J = 9, 2 Hz, 6-CH), 8.21 (1H, d, J = 9 Hz, 7-CH); m/z (EI)
303 (M[81Br]•+, 98%), 301 (M[79Br]•+, 96), 293 (17), 291 (13).
Methyl 3-bromo-5-nitrobenzo[b]thiophene-2-carboxylate
(13), from acid 12. According to a modified literature pro-
Paper Organic & Biomolecular Chemistry
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cedure,57 iodomethane (0.46 mL, 7.4 mmol) was added to a
solution of 3-bromo-5-nitrobenzo[b]thiophene-2-carboxylic
acid (12) (1.12 g, 3.7 mmol) and K2CO3 (1.28 g, 9.2 mmol) in
DMF (15 mL). After stirring at room temperature for 3 h, the
reaction mixture was quenched with saturated aqueous NH4Cl
solution, poured into excess water and filtered under reduced
pressure. The collected solid was washed with water and dried
in air to give the title compound (1.09 g, 93%) as an oﬀ-white
powder, mp 211.5–212.5 °C (lit.,40 mp 211–212 °C) (Found
[TOF MS]: 315.9279. C10H7
79BrNO4S [MH] requires 315.9279);
IR (neat) νmax/cm
−1 3101 (C–H), 1691 (CvO), 1600 (C–C), 1514
(NO2), 1347 (NO2), 1089 (C–O), 1052 (C–O), 617 (C–Br);
1H
NMR (500 MHz, CDCl3) δH/ppm 8.90 (1H, d, J = 2 Hz, 4-CH),
8.38 (1H, dd, J = 9, 2 Hz, 6-CH), 8.00 (1H, d, J = 9 Hz, 7-CH),
4.02 (3H, s, Me); 13C NMR (125 MHz, CDCl3) δc/ppm 161.0 (C),
146.5 (5-C), 144.6 (C), 138.9 (C), 131.0 (3α-C), 123.8 (7-CH),
122.2 (6-CH), 121.3 (4-CH), 115.6 (3-CH), 53.0 (Me); m/z (EI)
317 (M[81Br]•+, 100%), 315 (M[79Br]•+, 94), 286 (58), 284 (55).
Methyl 3-bromo-5-nitrobenzo[b]thiophene-2-carboxylate
(13), from 3-aminobenzothiophene 5b. Following the pro-
cedure of Iaroshenko et al.,60 CuBr2 (0.94 g, 4.2 mmol) was
added to a solution of tert-butyl nitrite (0.45 mL, 3.8 mmol) in
dry MeCN (11 mL) at 0 °C under argon. Methyl 3-amino-4-
nitrobenzo[b]thiophene-2-carboxylate (5b) (0.69 g, 2.7 mmol)
was then added portion-wise and the solution kept at 0 °C
until nitrogen evolution ceased. The reaction mixture was
allowed to warm to room temperature, stirred for 2 h and then
poured into dilute hydrochloric acid (10%; 25 mL). The
aqueous mixture was extracted with EtOAc (3 × 30 mL) and the
organic extracts were combined, dried (Na2SO4) and evapor-
ated in vacuo to give the title compound (0.86 g, 99%) as an
orange solid, mp 212.3–213.0 °C (acetone) (lit.,40 mp 211–212 °C),
with identical spectroscopic and spectrometric properties.
(E)-5-(2-Cyclopropylvinyl)-2-fluorobenzonitrile (14i). To a
solution containing 5-bromo-2-fluorobenzonitrile (14a) (3.0 g,
15.0 mmol), Pd(PPh3)2Cl2 (1.0 g, 1.5 mmol) and trans-2-cyclo-
propylvinylboronic acid pinacol ester (3.7 mL, 18 mmol) in
DME/EtOH/H2O (7 : 2 : 3) (50 mL) was added aqueous Na2CO3
solution (1 M; 27 mL). The resulting mixture was placed under
an atmosphere of nitrogen and heated at 80 °C for 16 h after
which time the reaction was cooled to room temperature and
filtered through Celite. Purification by flash column chromato-
graphy on silica gel, eluting with light petroleum–EtOAc (9 : 1),
gave the title compound (2.4 g, 86%) as a yellow oil (Found [ES+]:
188.0868. C12H11NF [MH] requires 188.0870); IR (neat) νmax/cm
−1
3007 (C–H), 2496 (CN), 1672 (CvC); 1H NMR (400 MHz, CDCl3)
δH/ppm 7.53–7.46 (2H, m), 7.16–7.08 (1H, m), 6.39 (1H, d, J =
15.7 Hz), 5.71 (1H, dd, J = 15.7, 9.0 Hz), 1.65–1.53 (1H, m),
0.92–0.84 (2H, m), 0.59–0.52 (2H, m); 13C NMR (101 MHz,
CDCl3) δC/ppm 161.7 (d, J = 258.2 Hz), 137.9, 135.3 (d, J = 3.5 Hz),
131.8 (d, J = 7.9 Hz), 130.0, 124.2, 116.5 (d, J = 20.3 Hz), 101.5 (d,
J = 15.7 Hz), 77.2, 14.7, 7.6; m/z (ES) 188 (MH+, 100%).
Methyl 3-aminothieno[2,3-b]pyridine-2-carboxylate (16).
2-Chloro-3-pyridinecarbonitrile (15b) (35 mg, 0.25 mmol),
methyl thioglycolate (0.22 mL, 0.25 mmol) and triethylamine
(0.10 mL, 0.72 mmol) were reacted according to the above
general procedure for 15 min to give the title compound
(36 mg, 69%) as a yellow solid, mp 191 °C (dec.) (lit.,13 mp
194–196 °C) (Found [ES+]: 209.0380. C9H9N2O2S [MH] requires
209.0385); IR (neat) νmax/cm
−1 3417 (N–H), 3314, 3202, 2943,
1679 (CvO), 1291 (C–O), 1127 (C–O); 1H NMR (500 MHz, d6-
DMSO) δH/ppm 8.68 (1H, dd, J = 4.6, 1.6 Hz, 6-CH), 8.54 (1H,
dd, J = 8.1, 1.6 Hz, 4-CH), 7.46 (1H, dd, J = 8.1, 4.6 Hz, 5-CH),
7.30 (2H, bs, NH2), 3.80 (3H, s, Me);
13C NMR (101 MHz,
d6-DMSO) δC/ppm 164.7 (CvO), 159.7 (7α-C), 150.7 (6-CH),
147.7 (3-C), 131.4 (4-CH), 125.5 (3α-C), 119.4 (5-CH), 93.2 (2-C),
51.4 (Me); m/z (EI) 208 (M•+, 100%), 177 (28), 176 (93), 148 (60).
1H NMR spectroscopic analyses were in good agreement with
literature data.13
tert-Butyl [(2R)-1-aminopropan-2-yl]carbamate (17). Accord-
ing to a modified literature procedure,72 a solution of Boc-D-
Ala-OH (0.50 g, 2.64 mmol) and HOBt·H2O (0.41 g, 3.0 mmol)
in CH2Cl2 (20 mL) was cooled to 0 °C and EDCI·HCl (0.58 g,
3.0 mmol) was added. The solution was allowed to warm to
room temperature and stirred for 30 min. The solution was
then cooled to 0 °C, aqueous NH3 (18.1 M; 0.6 mL) was added
drop-wise and the mixture was stirred at room temperature for
30 min. Any solid residue was removed by filtration and the fil-
trate was washed sequentially with water (20 mL) and brine
(2 × 20 mL), dried (MgSO4) and evaporated in vacuo. Purifi-
cation by flash column chromatography on SiO2, gradient
eluting with MeOH–CH2Cl2 (from 3–7% MeOH), gave Boc-D-
Ala-NH2 (0.37 g, 75%) as colourless crystals, mp
127.5–128.2 °C (lit.,73 mp 120–121 °C). According to a modi-
fied literature procedure,74 BH3·SMe2 (2 M in THF; 13.5 mL,
27 mmol) was added portion-wise to a solution Boc-D-Ala-NH2
(0.5 g, 2.7 mmol) in dry THF (9 mL) under N2 at 0 °C. The reac-
tion mixture was allowed to warm to room temperature, stirred
for 18 h, evaporated in vacuo and treated with MeOH (3 ×
15 mL), stirring and evaporating in vacuo each time. Purifi-
cation by ion exchange chromatography using an Isolute SPE
SCX-2 flash column, eluting first with MeOH and then with a
solution of NH3 in MeOH (2 M), gave the title compound
(0.39 g, 84%) as a colourless oil [Rf 0.3 in MeOH–CH2Cl2 (1 : 9)]
(Found [ES+]: 175.1443. C8H19N2O2 [MH] requires 175.1441);
[α]24D −5.7 (c 1.1, MeOH); IR (neat) νmax/cm−1 2973 (C–H), 1685
(CvO), 1521 (N–H), 1364 (CH3 deformation), 1247 (C–O), 1165
(C–N), 1045 (C–O), 872 (N–H); 1H NMR (500 MHz, CDCl3) δH/
ppm 4.78 (1H, m, NHBoc), 3.60 (1H, m, 2-CH), 2.70 (1H, m, 1-
CHH), 2.59 (1H, m, 1-CHH), 1.40 (9H, s, CMe3), 1.08 (3H, d, J =
7 Hz, 3-Me); 13C NMR (125 MHz, CDCl3) δC/ppm 155.7 (C),
79.1 (C), 48.6 (2-CH), 47.4 (4-CH2), 28.4 (CMe3), 18.5 (Me).
1H NMR spectroscopic analyses were in good agreement with
literature data.75
(R)-Methyl 3-((2-((tert-butoxycarbonyl)amino)propyl)amino)-
5-nitrobenzo[b]thiophene-2-carboxylate (18). According to a
modified literature procedure,76 (R)-tert-butyl (1-aminopropan-
2-yl)carbamate (17) (35 mg, 0.20 mmol) was added to a stirred
mixture of methyl 3-bromo-5-nitrobenzo[b]thiophene-2-carboxy-
late (13) (50 mg, 0.16 mmol), Cs2CO3 (73 mg, 0.22 mmol),
(±)-BINAP (13 mg, 0.02 mmol) and Pd(OAc)2 (2.0 mg, 8.0 μmol)
in dry toluene (1.0 mL) under N2 and the mixture was irra-
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diated at 150 °C for 75 min (hold time) in a pressure-rated
glass tube (10 mL) using a CEM Discover microwave synthesi-
zer by moderating the initial power (200 W). After cooling in a
flow of compressed air, the reaction mixture was partitioned
between water (20 mL) and EtOAc (30 mL). The aqueous layer
was further extracted with EtOAc (2 × 30 mL) and the organic
extracts were combined, washed with brine (30 mL), dried
(Na2SO4) and evaporated. Purification by flash column chrom-
atography on SiO2 (dry load), gradient eluting with light pet-
roleum to Et2O–light petroleum (1 : 1), gave the title compound
(50 mg, 76%) as a red solid, mp 182.9–184.0 °C (Found [ES+]:
410.1378. C18H24N3O6S [MH] requires 410.1380); [α]
24
D +55.3 (c
0.1, MeOH); IR (neat) νmax/cm
−1 3355 (N–H), 2954 (C–H), 1672
(CvO), 1588 (NO2) 1508 (C–C), 1325 (NO2), 1230 (C–O), 1060
(C–N); 1H NMR (500 MHz, d6-DMSO) δH/ppm 8.94 (1H, m, 4-
CH), 8.27 (1H, d, J = 9 Hz, 6-CH), 8.15 (1H, d, J = 9 Hz, 7-CH),
7.54 (1H, m, 3-NH), 6.87 (1H, d, J = 6 Hz, 2′-NH), 3.81 (4H, m,
1′-CHH and OMe), 3.76 (1H, m, 2′-CH), 3.57 (1H, m, 1′-CHH),
1.32 (9H, s, CMe3), 1.12 (1H, d, J = 6 Hz, 3′-Me);
13C NMR
(125 MHz, d6-DMSO) δC/ppm 164.0 (C), 155.1 (C), 150.3 (3-C),
145.2 (C), 144.3 (C), 131.1 (3α-C), 124.7 (7-CH), 121.6 (6-CH),
120.5 (4-CH), 99.5 (2-C), 77.6 (CMe3), 51.7 (OMe), 50.5 (1′-CH2),
46.2 (2′-CH), 28.1 (CMe3), 18.3 (3′-Me); m/z (EI) 410 (MH
+,
100%), 409 (M•+, 70).
Methyl 3-((1-amino-2-chloroethylidene)amino)-5-((E)-2-cyclo-
propylvinyl)benzo[b]thiophene-2-carboxylate hydrochloride (19).
Methyl (E)-3-amino-5-(2-cyclopropylvinyl)benzo[b]thiophene-
2-carboxylate (5i) (200 mg, 0.73 mmol) was suspended in a
solution of HCl in 1,4-dioxane (4 M; 3 mL) and chloro-
acetonitrile (91 μL, 1.43 mmol) was added drop-wise. The
reaction mixture was stirred at room temperature for 16 h
and the suspension was filtered under reduced pressure,
washed with light petroleum (60 mL) and dried in vacuo for
6 h to give the title compound (110 mg, 39%) as a colourless
solid, mp 195–197 °C (dec.) (Found [ES+]: 317.0512.
C16H14
35ClN2OS [MH − MeOH] requires 317.0515); IR (neat)
νmax/cm
−1 3332 (br, N–H), 3001 (C–H), 2675 (C–H), 1676
(CvO), 1620 (CvC); 1H NMR (400 MHz, CD3OD) δH/ppm 7.91
(1H, d, J = 8.6 Hz, 7-CH), 7.72 (1H, d, J = 1.5 Hz, 4-CH), 7.67
(1H, dd, J = 8.6, 1.5 Hz, 6-CH), 6.60 (1H, d, J = 15.8 Hz, CH),
5.96 (1H, dd, J = 15.8, 9.1 Hz, CH), 4.73 (2H, s, CH2), 3.94 (3H,
s, Me), 1.65–1.55 (1H, m, CH), 0.87–0.79 (2H, m, CHH),
0.59–0.48 (2H, m, CHH); 13C NMR (101 MHz, CD3OD) δC/ppm
166.3 (C), 162.4 (C), 138.9 (C), 138.3 (CH), 138.0 (C), 135.8 (C),
130.5 (C), 130.4 (C), 127.7 (CH), 127.3 (CH), 124.6 (CH), 119.6
(CH), 53.4 (Me), 40.1 (CH), 15.5 (CH), 7.8 (CH2, CH2); m/z (ES)
349 (M[35Cl]H+, 100%).
(E)-8-(2-Cyclopropylvinyl)-2-((dimethylamino)methyl)benzo-
[4,5]thieno[3,2-d]pyrimidin-4(3H)-one (20). Compound 19
(70 mg, 0.18 mmol) was added to a solution of dimethylamine
in ethanol (33%; 3 mL) and the reaction mixture was stirred at
room temperature for 16 h. The solvent was evaporated
in vacuo and the resulting colourless solid was dissolved in
MeOH–CH2Cl2 (1 : 1; 5 mL) and loaded onto an SCX cartridge
(1 g). The cartridge was flushed with MeOH (3 × 5 mL) and
then eluted with a solution of NH3 in MeOH (2 M; 8 mL) to
give the title compound as a colourless solid (55 mg, 94%), mp
202–203 °C (dec.) (Found [ES+]: 326.1324 C18H20N3OS [MH]
requires 326.1322); IR (neat) νmax/cm
−1 2873 (br, C–H), 1672
(CvO), 1587 (CvC); 1H NMR (400 MHz, d6-DMSO) δH/ppm
12.41 (1H, bs, NH), 8.09 (1H, d, J = 1.5 Hz, 4-CH), 8.03 (1H, d,
J = 8.5 Hz, 7-CH), 7.69 (1H, dd, J = 8.5, 1.5 Hz, 6-CH), 6.68 (1H,
d, J = 15.8 Hz, CH), 6.01 (1H, dd, J = 15.8, 9.2 Hz, CH), 3.52
(2H, s, CH2), 2.29 (6H, s, Me), 1.66–1.56 (1H, m, CH), 0.85–0.78
(2H, m, CHH), 0.61–0.54 (2H, m, CHH); 13C NMR (101 MHz,
d6-DMSO) δC/ppm 158.5 (C), 157.2 (C), 152.7 (C), 138.3 (C),
136.2 (CH), 135.2 (CH), 134.6 (C), 126.5 (C), 126.2 (CH), 123.9
(CH), 122.0 (C), 119.7 (CH), 61.3 (CH2), 45.1 (Me, Me), 14.7
(CH), 7.2 (CH2, CH2); m/z (ES) 326 (MH
+, 100%). 1H NMR spec-
troscopic analyses were in good agreement with literature data
for the corresponding HCl salt.15
Conclusions
This method for the microwave-assisted synthesis of 3-amino-
benzo[b]thiophenes is rapid, simple to carry out and generally
high yielding. It has been applied in the synthesis of a range
of functional benzothiophenes and their 7-aza analogues and
constitutes a very eﬃcient route to the corresponding 3-halo-
benzothiophenes using diazonium chemistry. Applications of
this process have been shown in the synthesis of the thieno-
[2,3-b]pyridine core motif of LIMK1 inhibitors using 2-halopyr-
idine-3-carbonitriles, the benzo[4,5]thieno[3,2-e][1,4]diazepin-
5(2H)-one scaﬀold of MK2 inhibitors with functionality suit-
able for subsequent modification using Buchwald–Hartwig
chemistry, and a benzo[4,5]thieno[3,2-d]pyrimidin-4-one target
as a chemical tool for inhibition of PIM kinases. In the case of
inhibitors of MK2, the use of this approach has been shown to
be superior to traditional bromination chemistry using the
parent benzothiophene heterocycle. Given the speed, eﬃciency
and reliability of these methods, and their ability to incorpor-
ate a wide range of functionality, these approaches are likely to
find application in providing chemical tools, rapidly, reliably
and eﬃciently, for advancing studies in chemical biology, as
well as to access targets in medicinal chemistry.
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